AngioDynamics (NASDAQ:ANGO) Stock Price Down 7.1% – Should You Sell?

06 Oct 2026, 18:01 by Michael Walen · The Markets Daily

AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report)’s share price was down 7.1% during mid-day trading on Tuesday. The stock traded as low as $14.51 and last traded at $14.4350. 272,285 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 478,868 shares. The stock had previously closed at $15.54.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. HC Wainwright lifted their target price on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Canaccord Genuity Group upped their price target on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, AngioDynamics currently has a consensus rating of “Hold” and a consensus target price of $19.50.

Read Our Latest Report on ANGO

AngioDynamics Stock Performance

The stock’s fifty day moving average price is $15.47 and its two-hundred day moving average price is $13.06. The company has a market cap of $606.66 million, a P/E ratio of -16.60 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities research analysts forecast that AngioDynamics, Inc. will post -0.25 EPS for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of AngioDynamics in the second quarter worth approximately $49,480,000. Armistice Capital LLC boosted its holdings in AngioDynamics by 3.9% during the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after purchasing an additional 64,000 shares during the last quarter. Weber Capital Management LLC ADV bought a new stake in AngioDynamics in the 2nd quarter worth about $17,649,392. Bastion Asset Management Inc. increased its stake in AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after buying an additional 194,822 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in AngioDynamics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock valued at $10,786,000 after buying an additional 32,476 shares during the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.